We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -14.00 | -0.12% | 12,156.00 | 12,126.00 | 12,128.00 | 12,258.00 | 12,114.00 | 12,114.00 | 1,961,686 | 16:35:29 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.57 | 188.01B |
From May 2019 to May 2024
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) said Monday that a phase 3 study of diabetes medication Farxiga showed the drug lowered the risk of kidney-function decline.
The data from the Declare-Timi 58 trial showed that patients with type-2 diabetes administered Farxiga showed a 47% reduction in the relative risk of the composite renal-specific outcome of kidney function decline--a measure of how well the kidney filters the blood--when compared with placebo.
Joris Silon, senior vice president of AstraZeneca's cardiovascular, renal and metabolism unit, said the data continues to support the consistent cardio-renal results demonstrated by Farxiga, across a large and broad everyday patient population.
The clinical trial first reported headline results in November.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
June 10, 2019 01:20 ET (05:20 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
